NCT00398424已完成1 期
A Phase I, Open-Label Study Evaluating The Pharmacokinetics of Components of S-1 Patients With Impaired Hepatic Function
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 12
- 主要终点
- To provide specific dosing recommendations for S-1 in patients with hepatic impairment based on the PK of S-1 and its components after single dose and during steady state condition
研究概览
简要总结
This is a Phase I, Open-Label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of hepatic function defined by the NCI classification for hepatic impairment. Patients will be stratified into 4 Cohorts- Normal, Mild, Moderate or Severe.
Six patients will be enrolled inot each cohort and receive S-1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- •Has histologically or cytologically proven advanced solid tumors for which no standard therapy exists.
- •Has provided written informed consent.
- •Is 18 years of age or older.
- •Is able to take medications orally.
- •Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to ≤ 2 (Appendix A, ECOG Performance Status).
- •Has adequate organ function as defined by the following criteria:
- •Absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International Units [IU]).
- •Has a platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).
- •Has a hemoglobin value of ≥ 9.0 g/dL.
- •Has a calculated creatinine clearance > 60 mL/min (by Cockcroft-Gault
- •Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Exclusion Criteria
- •Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
- •Has had treatment with any of the following within the specified time frame prior to study drug administration:
- •Any investigational agent received either concurrently or within the last 30 days.
- •Previous therapy for malignancy within 21 days, including any chemotherapy, immunotherapy, biologic or hormonal therapy (6 weeks for nitrosoureas or mitomycin C).
- •Previous radiotherapy within 14 days.
- •Current enrollment in another clinical trial.
- •Required shunting or stenting of the liver within prior 28 days or planned during the first study treatment cycle.
- •Has a serious illness or medical condition(s) including, but not limited to, the following:
- •Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] Class III or IV, see Appendix F, NYHA Classification).
- •Known (at the time of entry) gastrointestinal disorder, including malabsorption,chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.
- •Previous organ allograft, including liver transplantation.
- •Known brain metastasis.
- •Known leptomeningeal metastases.
- •Manifest ascites.
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study. •
- •Is receiving a concomitant treatment with drugs interacting with S-
- •The following drugs are prohibited because there may be an interaction with S-1:
- •Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1 activity).
- •Allopurinol (may diminish S-1 activity).
- •Phenytoin (S-1 may enhance phenytoin activity).
- •Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and flucytosine activity).
- •Pilocarpine (may inhibit CYP2A6 activity).
- •Has known sensitivity to 5-FU.
- •Is a pregnant or lactating female.
- •Is a patient with reproductive potential who refuses to use an adequate means of contraception (including male patients).
排除标准
- 未提供
结局指标
主要结局
To provide specific dosing recommendations for S-1 in patients with hepatic impairment based on the PK of S-1 and its components after single dose and during steady state condition
时间窗: The Pharmacokinetic Phase (Part 1) of the study will last 24 days.
次要结局
- To assess the antitumor activity and safety profile of S-1 in patients with impaired hepatic function(Each cycle of the Extension Phase (Part 2) will be 21 days (14 days of S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1.)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
1 期
Evaluating Patients With Varying Degrees of Renal FunctionRenal ImpairmentNCT00398307Taiho Oncology, Inc.24
已完成
1 期
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese VolunteersTransthyretin-mediated AmyloidosisNCT06527755AstraZeneca12
已完成
1 期
Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual OnychomycosisOnychomycosis of ToenailNCT05110638SATO Pharmaceutical Co., Ltd.19
已完成
1 期
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.Parkinson DiseaseNCT03496870Neurocrine Biosciences16
已完成
1 期
A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male ParticipantsHealthy VolunteersNCT05847439Bristol-Myers Squibb8